Oxybutynine [Inn-French]

Oxybutynine [Inn-French] Brand names, Oxybutynine [Inn-French] Analogs

Oxybutynine [Inn-French] Brand Names Mixture

No information avaliable

Oxybutynine [Inn-French] Chemical_Formula

C₂₂H₃₁NO₃

Oxybutynine [Inn-French] RX_link

http://www.rxlist.com/cgi/generic/ditropan.htm

Oxybutynine [Inn-French] fda sheet

Oxybutynine_[Inn-French] FDA

Oxybutynine [Inn-French] msds (material safety sheet)

Oxybutynine_[Inn-French] MSDS

Oxybutynine [Inn-French] Synthesis Reference

Brit. pat. 940540 (1963 to Mead Johnson)

Oxybutynine [Inn-French] Molecular Weight

357.486 g/mol

Oxybutynine [Inn-French] Melting Point

129-130 ^oC

Oxybutynine [Inn-French] H₂O Solubility

No information avaliable

Oxybutynine [Inn-French] State

Solid

Oxybutynine [Inn-French] LogP

4.683

Oxybutynine [Inn-French] Dosage Forms

Patch; Syrup; Tablet; Tablet (extended-release)

Oxybutynine [Inn-French] Indication

For the treatment of overactive bladder.

Oxybutynine [Inn-French] Pharmacology

Oxybutynin is an antispasmodic, anticholinergic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin relaxes bladder smooth muscle. Oxybutynin exhibits only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to ten times the antispasmodic activity. Antimuscarinic activity resides predominantly in the R-isomer.

Oxybutynine [Inn-French] Absorption

Rapidly absorbed from gastrointestinal tract.

Oxybutynine [Inn-French] side effects and Toxicity

LD₅₀=1220 mg/kg (Orally in rats, Goldenthal)

Oxybutynine [Inn-French] Patient Information

PATIENT INFORMATION
Patient should be informed that oxybutynin may produce drowsiness or blurred vision. Alcohal may enhance the drowsiness caused by anticholinergic agents. Fever and heat stroke can occur while anticholinergics are administered in the presence of high environmental temparature. Medication should be taken with the aid of liquids at approximately the same time each day. Patients should not chew, divide, or crush tablets.

Oxybutynine [Inn-French] Organisms Affected

Humans and other mammals